Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

MULTIPLE MYELOMA THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Multiple Myeloma Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 75 companies including many key and niche players such as Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Janssen Biotech, Inc., Millennium Pharmaceuticals, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1857
Price : $4500
Companies : 75
Pages : 595
Date : October 2011
Market Data Tables : 171
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  MULTIPLE MYELOMA THERAPEUTICS (Complete Report) Pages : 595   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-13 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
  2. INDUSTRY OVERVIEW.....II-53 $595  
   Robust Growth Ahead for Myeloma Therapeutics Market.....II-5
Multiple Myeloma: A Second Most Common Hematological Cancer.....II-5
1$100
   Table 1: Global Multiple Myeloma Disease Statistics: 2010 (includes corresponding Graph/Chart).....II-6

Table 2: Global Multiple Myeloma Patient Population in Thousands under Treatment by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Market Share Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis, Celgene, and Others (includes corresponding Graph/Chart).....II-7
US Remains the Largest Market; Rest of World to Spearhead Growth.....II-7
1$350
  3. MULTIPLE MYELOMA DRUGS MARKET – AN OVERVIEW.....II-811 $1450  
   The Myeloma Drug Domain.....II-8
Table 4: Annual Revenues of Select Multiple Myeloma Drugs Worldwide: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart).....II-8
Revlimid Outshines Other Leading Drugs.....II-8
1$350
   Velcade – Still the Most Superior in terms of Survival Rate.....II-9
Table 5: Sales of Velcade in the US and Rest of World: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart).....II-9
Subcutaneous Infusion – A Refuge for Velcade from Nueropathy?.....II-9
1$350
   Unmet Needs Drive Further Innovation in the Therapeutic Area.....II-10
Promising Drugs on the Anvil, Potential Market Remains Uncertain.....II-10
Revlimid – A Key Revenue Generator for Celgene.....II-10
1$100
   Table 6: Sales of Revlimid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart).....II-11

Table 7: Sales of Thalomid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart).....II-11
1$350
   Doxil Regains Sales Momentum.....II-12
Treatment Therapies: Move Up the Learning Curve.....II-12
Risk-Adapted Therapy: The New Norm of Future Treatment.....II-12
1$100
   New Generation Drugs in the Arsenal Against Multiple Myeloma.....II-13
Revlimid® (lenalidomide).....II-13
Velcade® (bortezomib).....II-13
Thalomid® (thalidomide).....II-13
1$100
   Doxil (liposomal doxorubicin).....II-14
Alkeran (melphalan).....II-14
Trisenox® (arsenic trioxide).....II-14
Select Promising Pipeline Drugs.....II-14
Carfilzomib (Onyx Pharmaceuticals).....II-14
1$100
   Phase II Results of Carfilzomib.....II-15
Pomalidomide (Celgene).....II-15
1$100
   Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons.....II-16
Revlimid Overtakes Thalomid: Why?.....II-16
How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows .....II-16
1$100
   Revlimid Impedes Stem Cell Harvesting!!: What’s the Truth?.....II-17
Other Trends & Issues.....II-17
Approval of New Generation Drugs Push the Market Into the Bulge Bracket.....II-17
Growth Fundamentals Get Stronger.....II-17
Multidrug Resistance: A Challenge to Reckon With.....II-17
1$100
   Gene Therapy Exudes Hope.....II-181$100
  4. CLINICAL TRIALS FOR MULTIPLE MYELOMA.....II-1917 $1450  
   Focus on Select Mid- and Late-Stage Clinical Trials in Multiple Myeloma.....II-19
Lenalidomide versus Placebo Maintenance Treatment post Single AHSCT for
  Myeloma.....II-19
Lenalidomide Maintenance Therapy Post Stem Cell Transplantation for Myeloma.....II-19
1$100
   Doxorubicin + Bortezomib + Dexamethasone versus VAD Ensued by High-Dose Melphalan and
  Maintenance with Thalidomide/Bortezomib in Newly Diagnosed MM Patients ......II-20
Weekly Bortezomib Maintenance Therapy Following Bortezomib-based Induction Therapy in
  Recently Diagnosed, Aged MM Sufferers .......II-20
1$100
   Lenalidomide in Combination with Prednisone and Melphalan in Recently Diagnosed
  Patients Above 65 years of Age ......II-21
Bortezomib + Prednisone + Melphalan, and Thalidomide Ensued by Thalidomide +
  Bortezomib Maintenance for Preliminary Treatment of Aged MM Patients.....II-21
Lenalidomide + Dexamethasone + Carfilzomib in Recently Diagnosed Multiple
  Myeloma.....II-21
1$100
   Carfilzomib in Refractory and Relapsed MM Setting.....II-22
Carfilzomib as Standalone Therapy in Relapsed or Refractory MM.....II-22
1$100
   Combination of Vorinostat and Lenalidomide + Bortezomib in Relapsed/Refractory
  Multiple Myeloma.....II-23
Carfilzomib in Refractory/Relapsed MM Patients (for Long-Term Tolerability and
  Treatment).....II-23
1$100
   Multiple Myeloma Drugs In Pipeline in the Us As of the Year 2008.....II-24
Phase III Drugs in Pipeline.....II-24
1$100
   Phase II Drugs in Pipeline.....II-256$600
   Phase I Drugs in Pipeline.....II-315$500
  5. HEMATOLOGICAL CANCERS – AN OVERVIEW & THERAPIES.....II-363 $295  
   Hematological Cancer Therapies: A Prelude.....II-36
Treatment Regimes: The Golden Rule.....II-36
1$100
   Challenges Encountered in Clinical Trials.....II-371$100
   FDA’s Antidotes.....II-381$100
  6. DISEASE & TREATMENT OVERVIEW.....II-3912 $950  
   Cancer: A Definition.....II-39
Hematological Cancers.....II-39
Types of Hematological Cancer.....II-39
Multiple Myeloma.....II-39
1$100
   Multiple Myeloma Stages.....II-40
Stage I.....II-40
Stage II/III.....II-40
Treatment Procedures.....II-40
Diagnosis.....II-40
1$100
   Treatment.....II-41
Initial Treatment Regimen.....II-41
Induction Therapy for SCT Candidates.....II-41
1$100
   Induction Therapy for Non-SCT Candidates.....II-42
Therapy for Relapsed or Refractory Myeloma.....II-42
Maintenance Therapy for Relapsed or Refractory Myeloma.....II-42
Treatment Pros & Cons.....II-42
1$100
   Other Types of Hematological Cancers.....II-43
Leukemia.....II-43
1$100
   Acute Lymphocytic Leukemia.....II-44
Chronic Lymphocytic Leukemia.....II-44
Acute Myeloid Leukemia.....II-44
Chronic Myeloid Leukemia.....II-44
1$100
   Lymphoma.....II-45
Non-Hodgkin’s Lymphoma.....II-45
Hodgkin’s Lymphoma.....II-45
1$100
   Myelodysplastic Syndromes.....II-46
Hematological Cancer Therapies.....II-46
Chemotherapy.....II-46
Radiation Therapy.....II-46
1$100
   Stem Cell Transplants.....II-47
Biological Therapy.....II-47
Targeted Therapy.....II-47
1$100
   Gene Therapy.....II-48
Immunotherapy.....II-48
Monoclonal Antibody Treatment.....II-48
1$100
   Vaccines.....II-49
Donor Lymphocyte Infusion.....II-49
Hematological Cancer Drug Classes.....II-49
Hypomethylating Agents & Antimetabolites.....II-49
Bisphosphonates.....II-49
Alkylating Agents and DNA-Damaging Agents.....II-49
1$100
   DNA-Repair Enzyme Inhibitors.....II-50
Histone Deacetylase Inhibitor.....II-50
Immunomodulators.....II-50
Proteasome Inhibitor.....II-50
Tyrosine Kinase Inhibitors.....II-50
1$100
  7. DRUG APPROVALS/LAUNCHES.....II-5110 $595  
   Celgene Launches Revlimid and Lenadex Drugs in Japan.....II-51
Millennium Receives FDA Approval for Supplemental NDA of VELCADE.....II-51
Intas Introduces Bortezomib Injection for Treating Multiple Myeloma in India.....II-51
NICE Grants Approval for Use of Revlimid®.....II-51
1$100
   SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple
  Myeloma.....II-52
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide.....II-52
Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug.....II-52
FDA Grants Orphan-Drug Designation to Melphalan.....II-52
1$100
   Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza.....II-53
Clavis Initiates Phase II Trial of Elacytarabine.....II-53
Gilead Sciences Commences GS 9219 Phase I Clinical Trial.....II-53
AstraZeneca Carries Out AZD 0530 Phase II trial.....II-53
1$100
   European Commission Grants Approval of Thalidomide for Multiple Myeloma.....II-54
EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma.....II-54
Global Regulatory Developments for the Use of Revlimid® in Multiple Myeloma.....II-54
1$100
   Takeda Gains FDA Approval to Promote Velcade.....II-55
Health Canada Approves VELCADE.....II-55
Genzyme Receives FDA Certification for Mozobil.....II-55
1$100
   Celgene’s Thalidomide Pharmion Receives Marketing Authorization.....II-56
Ziopharm Commences Phase II Clinical Trial of ZIO-101.....II-56
FDA Approves Pluristem’s Pre-IND Application of PLX-I.....II-56
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor.....II-56
1$100
   Swissmedic Approves Celgene’s REVLIMID Oral Cancer Drug.....II-57
Celgene’s REVLIMID Receives EU’s Marketing Authorization.....II-57
FDA Approves Application of Piramal’s IND-P276 Multiple Myeloma Drug.....II-57
Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase II
  Trial.....II-57
1$100
   FDA to Consider the New Drug Application Filed for Use of Doxil® Combined with Velcade®
  in Patients with Multiple Myeloma.....II-58
Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL® and
  VELCADE®.....II-58
Caraco’s Allopurinol Receives FDA Approval.....II-58
FDA Approves Thalomid® as Combination Therapy for Multiple Myeloma.....II-58
1$100
   Revlimid® Obtains Regulatory Approval for the Treatment of Multiple Myeloma.....II-59
LymphoSign Inc. Announces Successful Completion of LS104 Drug’s Pre-Clinical
  Testing.....II-59
Seattle Genetics Commences SGN-40 Phase I Clinical Trial.....II-59
FDA Approves Use of Revlimid® for Multiple Myeloma.....II-59
US FDA Approves Use of Thalidomide for Multiple Myeloma.....II-59
Ziopharm Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial.....II-59
1$100
   FDA Grants Approval for Use of VELCADE® for Patients with Mantle Cell Lymphoma.....II-601$100
  8. RECENT INDUSTRY ACTIVITY.....II-6119 $1450  
   Onyx Files NDA for Carfilzomib in Myeloma Treatment.....II-61
XTL Gains Orphan Drug Designation for rHuEPO.....II-61
Signal Genetics Enters into a Commercialization Agreement with NeoGenomics
  Laboratories.....II-61
1$100
   The Leukemia & Lymphoma Society Forms Alliance with Acetylon Pharmaceuticals.....II-62
Onyx Pharmaceuticals Gains FDA Fast Track Designation for Carfilzomib.....II-62
MMRF Enters into Collaboration with Astellas Pharma.....II-62
Takeda and Millennium Submit Two sNDA to FDA for Bortezomib.....II-62
1$100
   Astex Enters into Definitive Merger Agreement with SuperGen.....II-63
Yakult Honsha Enters into an Agreement with Aeterna Zentaris.....II-63
Celgene Submits MAA for REVLIMID in Europe.....II-63
1$100
   BMS Halts Tanespimycin Development.....II-64
Acetylon Releases Pre-Clinical Data for ACY-1215 in Multiple Myeloma.....II-64
Intellikine and MMRC Initiate Phase I Clinical Trial of INK128.....II-64
Celgene Gains MHLW Approval for REVLIMID in Japan.....II-64
1$100
   XTL Acquires Bio-Gal.....II-65
Compugen Discovers New Drug Target for Treating Multiple Myeloma.....II-65
Boehringer Ingelheim Enters into a Collaboration Agreement with Micromet.....II-65
1$100
   Abbott Acquires Facet Biotech.....II-66
Mannkind Enters Into a Research Agreement with MMRF.....II-66
Genentech Terminates Collaboration Agreement with Seattle for SGN-40.....II-66
1$100
   Keryx Gains Fast Track Designation for Perifosine from FDA.....II-67
FDA Clears Perifosine for Phase III Clinical Trials in Multiple Myeloma.....II-67
CyDex Receives FDA Approval for Clinical Evaluation of CDX-353.....II-67
1$100
   Onyx Acquires Proteolix.....II-68
Johnson & Johnson to Acquire Cougar.....II-68
Janssen and Takeda Ink Co-Promotion Agreement.....II-68
1$100
   Eisai Establishes Subsidiary in Canada.....II-69
Roche Group and ImmunoCellular Therapeutics Ink Licensing Agreement.....II-69
CytRx Acquires Innovive.....II-69
1$100
   Launch of Epoetin alfa Hexal.....II-70
PDL and Bristol-Myers Signs Agreement.....II-70
MNKD and LLS Conclude Joint Research Agreement.....II-70
MorphoSys and DSM Enter into Agreement.....II-70
1$100
   StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India.....II-71
ImmunoCellular Acquires Molecular Antibody Technology.....II-71
US House of Representatives Sanction the Hematological Cancer Research Investment and
  Education Act.....II-71
Bayer and Cell Therapeutics Enter into Mutual Agreement.....II-71
1$100
   Bristol-Myers Takes Over Kosan Biosciences.....II-72
Bristol and PDL BioPharma Enter into Agreement.....II-72
Gamida Cell Enters Into a Agreement with Amgen.....II-72
Circadian Acquires Complete Stake in Vegenics.....II-72
1$100
   Takeda Acquires Millennium Pharmaceuticals.....II-73
Access Pharmaceuticals Acquires Somanta.....II-73
Celgene Acquires Pharmion.....II-73
1$100
   GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics.....II-74
Cyclacel Acquires ALIGN Pharmaceuticals.....II-74
1$100
   Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer
  Drug.....II-75
Aegera Therapeutics Acquires LymphoSign Inc.....II-75
Velcade Gains Subsidy.....II-75
Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira
  Pharmaceuticals.....II-75
1$100
   MilleGen Enters into Collaboration with LFB.....II-76
TopoTarget Acquires Apoxis SA.....II-76
Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics.....II-76
PerkinElmer Takes Over ViaCell.....II-76
1$100
   Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa.....II-77
Johnson & Johnson Secures Contract worth US$112 Million.....II-77
Bioniche Pharma Acquires Branded Pharmaceutical from Nabi Biopharmaceuticals.....II-77
Takara Bio's RetroNect Used for Clinical Trials of Gene Therapy in Australia.....II-77
1$100
   MDS Pharma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D.....II-78
Celgene Certifies McKesson Specialty to Launch Revlimid.....II-78
Medarex and PacMab to Co-Develop Blood Cancer Therapies.....II-78
Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies.....II-78
1$100
   GlaxoSmithKline Takes Over Praecis Pharmaceuticals.....II-79
Biotest Acquires ImmunoGen Anticancer Technology Rights.....II-79
Hana Signs Licensing Agreement with Inex.....II-79
Cephalon Acquires Zeneus.....II-79
1$100
  9. FOCUS ON SELECT PLAYERS.....II-803 $295  
   Amgen, Inc. (USA).....II-80
Bristol-Myers Squibb Company (USA).....II-80
Celgene Corporation (USA).....II-80
F. Hoffmann-La Roche Ltd (Switzerland).....II-80
1$100
   Genentech, Inc. (USA).....II-81
Janssen Biotech, Inc. (USA).....II-81
Millennium Pharmaceuticals (USA).....II-81
Seattle Genetics (USA).....II-81
1$100
   Ziopharm Oncology, Inc. (USA).....II-821$100
  10. GLOBAL MARKET PERSPECTIVE.....II-83   
   Table 8: World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-831$350
   Table 9: World Historic Review for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-841$350
   Table 10: World 15-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-851$350
  11. THE UNITED STATES.....II-8616 $2950  
   A. Market Analysis.....II-86
Current & Future Analysis.....II-86
US Myeloma Statistics.....II-86
Table 11: Multiple Myeloma Disease Statistics in the US: 2010 (includes corresponding Graph/Chart).....II-86

Table 12: Addressable Multiple Myeloma Patient Population in the US by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-86
1$350
   Table 13: Hematological Malignancies in the US (2009): Number of Incidences by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart).....II-871$350
   Table 14: Hematological Malignancies in the US (2009): Number of Deaths by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart).....II-88

Table 15: Blood Cancer Statistics in the US (2010): Percentage Breakdown of Hematological Cancer Cases by Type: Lymphoma, Myeloma, and Leukemia (includes corresponding Graph/Chart).....II-88
Trends in Myeloma Therapeutics in the US.....II-88
Doctors Shift to Continuous Therapy in Myeloma Treatment.....II-88
1$350
   Table 16: Key Drug Regimens in the US Multiple Myeloma Market (2006): Breakdown of Typical Length of Treatment Cycle and Cost per Cycle (In US$) (includes corresponding Graph/Chart).....II-891$350
   Market Share Statistics.....II-90
Table 17: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-90

Table 18: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-90

Table 19: US Market for Multiple Myeloma Therapeutics (2010): Percentage Market Share Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-90
Key Non-Profit Organizations in the US.....II-90
1$350
   Multiple Myeloma Research Foundation (MMRF).....II-91
National Coalition for Cancer Survivorship (NCCS).....II-91
National Marrow Donor Program (NMDP).....II-91
Oregon Health and Science University Cancer Institute.....II-91
Drug Approvals.....II-91
1$100
   Strategic Corporate Developments.....II-926$600
   Focus on Select Key Players.....II-982$200
   B. Market Analytics.....II-100
Table 20: The US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-100
1$350
   Table 21: US Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1011$350
  12. JAPAN.....II-1024 $950  
   A. Market Analysis.....II-102
Current & Future Analysis.....II-102
Myeloma in Japan.....II-102
Table 22: Multiple Myeloma Disease Statistics in Japan: 2010 (includes corresponding Graph/Chart).....II-102

Table 23: Addressable Multiple Myeloma Patient Population in Japan by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-102
Drug Launches.....II-102
1$350
   Strategic Corporate Developments.....II-1031$100
   B. Market Analytics.....II-104
Table 24: Japanese Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-104
1$350
   Table 25: Japanese Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1051$350
  13. EUROPE.....II-1065 $950  
   A. Market Analysis.....II-106
Current & Future Analysis.....II-106
Myeloma in the EU – A Statistical Review.....II-106
Table 26: Multiple Myeloma Disease Statistics in the EU: 2010 (includes corresponding Graph/Chart).....II-106

Table 27: Addressable Multiple Myeloma Patient Population in the EU by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-106

Table 28: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-106
1$350
   Table 29: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-107
Europe Lagging Behind in Drug Approvals.....II-107
Thalidomide Takes Rebirth in the UK NHS.....II-107
Strategic Corporate Developments.....II-107
1$350
   F. Hoffmann-La Roche Ltd (Switzerland) – A Key Player.....II-1081$100
   B. Market Analytics.....II-109
Table 30: European Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-109
1$350
   Table 31: European Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1101$350
  14. REST OF WORLD.....II-1114 $950  
   A. Market Analysis.....II-111
Current & Future Analysis.....II-111
Strategic Corporate Developments.....II-111
1$100
   Drug Launch.....II-1121$100
   B. Market Analytics.....II-113
Table 32: Rest of World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-113
1$350
   Table 33: Rest of World Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1141$350
COMPETITION 469$995
  
Total Companies Profiled: 75 (including Divisions/Subsidiaries - 80)

Region/Country                 Players


The United States                 56    
Canada                             1
Japan                              6
Europe                            13 
     Germany                       5
     The United Kingdom            1
     Italy                         1
     Spain                         1
     Rest of Europe                5
Asia-Pacific (Excluding Japan)     3
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign